This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
search
Boston

ProtaGene will target CGT sector under new CEO

Posted by on 03 October 2022
Share this article

ProtaGene says fast growing cell and gene therapy sector will be a target under newly appointed CEO, Raymond Kaiser.

The analytical services focused CRO shared details of the growth plan this week shortly after naming Kaiser as its new chief.

A spokeswoman said “ProtaGene is strong already in biologics and with the cell and gene therapy field rapidly growing, we intend to push the company to be an analytic partner of choice for cell and gene therapy companies both in the US and European markets.

“We’ll also better leverage the global needs to keep up with the demands from the market -- from discovery to commercial launch,” she told Clinical Insider.

The firm will aim to be flexible to capture demand the spokeswoman told us.

“ProtaGene is focused on increasing cell and gene capabilities and capacity – the field is rapidly growing, and we are seeing new emerging modalities,” she said, adding “We must adapt to what the pharma market is adopting with different proteins.”

Mass spec

Innovative analytical technologies and increased capacity will be core to ProtaGene’s effort to grow its cell and gene therapy business.

According to the spokeswomen “advanced analytical techniques are enabling technologies that open the door for new therapeutic ideas to become commercial realities.”

She cited mass spectrometry as an example, explaining “Mass Spec is in Ray’s DNA. It’s where his career began, and it is one of ProtaGene’s biggest strengths.”

She also highlighted the German-American CRO recently opened laboratory just outside Boston as an example of ProtaGene’s growth efforts, explaining the facility will cater for growing demand from US customers for analytical services.

Kaiser joined ProtaGene as chief operating officer earlier this year has replaced former CEO Martin Blüggel, who founded the firm in 1997.

ProtaGene was formed last year through the merger of ProtaGene Protein Services, BioAnalytix and GeneWerk.

DepositPhotos/artursz

Share this article

Sign up for Clinical Insider email updates

keyboard_arrow_down